Change search
ReferencesLink to record
Permanent link

Direct link
Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake
KTH, School of Biotechnology (BIO).
Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University.
Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University.
Section of Hospital Physics, Department of Oncology, Uppsala University Hospital.
Show others and affiliations
2008 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 35, no 12, 2245-2255 p.Article in journal (Refereed) Published
Abstract [en]

Purpose  Affibody molecules are low molecular weight proteins (7 kDa), which can be selected to bind to tumour-associated target proteins with subnanomolar affinity. Because of rapid tumour localisation and clearance from nonspecific compartments, Affibody molecules are promising tracers for molecular imaging. Earlier, 99mTc-labelled Affibody molecules demonstrated specific targeting of tumour xenografts. However, the biodistribution was suboptimal either because of hepatobiliary excretion or high renal uptake of the radioactivity. The goal of this study was to optimise the biodistribution of Affibody molecules by chelator engineering. Materials and methods  Anti-HER2 ZHER2:342 Affibody molecules, carrying the mercaptoacetyl-glutamyl-seryl-glutamyl (maESE), mercaptoacetyl-glutamyl-glutamyl-seryl (maEES) and mercaptoacetyl-seryl-glutamyl-glutamyl (maSEE) chelators, were prepared by peptide synthesis and labelled with 99mTc. The tumour-targeting capacity of these conjugates was compared with each other and with the best previously available conjugate, 99mTc-maEEE-ZHER2:342, in nude mice bearing SKOV-3 xenografts. The tumour-targeting capacity of the most promising conjugate, 99mTc-maESE-ZHER2:342, was compared with radioiodinated ZHER2:342. Results  All novel conjugates demonstrated successful tumour targeting and a low degree of hepatobiliary excretion. The renal uptakes of serine-containing conjugates, 33 ± 5, 68 ± 21 and 71 ± 10%IA/g, for99mTc-maESE-ZHER2:342, 99mTc-maEES-ZHER2:342 and 99mTc-maSEE-ZHER2:342, respectively, were significantly reduced in comparison with 99mTc-maEEE-ZHER2:342 (102 ± 13%IA/g). For 99mTc-maESE-ZHER2:342, a tumour uptake of 9.6 ± 1.8%IA/g and a tumour-to-blood ratio of 58 ± 6 were reached at 4 h p.i. Conclusions  A combination of serine and glutamic acid residues in the chelator sequence confers increased renal excretion and relatively low renal uptake of 99mTc-labelled Affibody molecules. In combination with preserved targeting capacity, this improved imaging of targets in abdominal area.

Place, publisher, year, edition, pages
2008. Vol. 35, no 12, 2245-2255 p.
Keyword [en]
Affibody molecule; HER2; Renal uptake; Technetium-99m; Tumour targeting
National Category
Medical and Health Sciences
URN: urn:nbn:se:kth:diva-9724DOI: 10.1007/s00259-008-0845-7ISI: 000261654000012ScopusID: 2-s2.0-58149305658OAI: diva2:127222
QC 20100716. Uppdaterad från in press till published (20100716).Available from: 2008-12-03 Created: 2008-12-03 Last updated: 2010-07-16Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Ekblad, TorunEriksson Karlström, Amelie
By organisation
School of Biotechnology (BIO)
In the same journal
European Journal of Nuclear Medicine and Molecular Imaging
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 51 hits
ReferencesLink to record
Permanent link

Direct link